Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia

European Journal of Clinical Investigation, Supplement

Volumn 34, Issue 2, 2004, Pages 25-30

  Gaiger, A ^a   Heintel, D ^a   Jäger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CLL; Microarray analysis; Molecular markers; Prognostic factors; Therapeutic targets

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CHLORAMBUCIL; DEPSIPEPTIDE; FLUDARABINE; FR 901228; MIDOSTAURIN; MOLECULAR MARKER; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PICEATANNOL; PROTEASOME INHIBITOR; PSI 341; RAPAMYCIN; RITUXIMAB; UNCLASSIFIED DRUG; VACCINE; WORTMANNIN;

APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC VALUE; DNA MICROARRAY; DRUG TARGETING; GENE THERAPY; GENOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOLECULAR BIOLOGY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; VALIDATION PROCESS; B CELL LEUKEMIA; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; POLYMERASE CHAIN REACTION; STAGING;

EID: 4944225952     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0960-135x.2004.01367.x     Document Type: Review

References (70)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7.
2. Kipps TJ. Chronic lymphocytic leukaemia. Curr Opin Hematol 2000;7:223-34.
3. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
4. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855-64.
5. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986;62:567-75.
6. Reinisch W, Willheim M, Hilgarth M, Gasche C, Mader R et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994;12:2146-52.
7. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:1732-7.
8. Heintel D, Schwarzinger I, Chizzali-Bonfadin C, Thalhammer R, Schwarzmeier J et al. Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia. Leuk Lymphoma 2001;42:1315-21.
9. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
10. Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-22.
11. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
12. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
13. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-9.
14. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA et al. Multivariate analysis of prognostic factors in CLL. Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84.
15. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Stood 2002;100:1410-6.
16. Thunberg U, Johnson A, Roos G, Thorn I, Tobin G et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001;97:1892-4.
17. Stilgenbauer S, Bullinger L, Lichter P, Dohner H, German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia. Genomic aberrations andV(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002;16:993-1007.
18. Tobin G, Thunberg U, Johnson A et Thorn I, Soderberg O, Hultdin M et al. Somatically mutated IgV(H) 3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-4.
19. Guarini A, Gaidano G, Mauro FR, Capello D, Mancini F et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenorypic and genorypic features. Blood 2003;102:1035-41.
20. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000;343:1799-801.
21. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998;338:1506-14.
22. Stilgenbauer S, Kröber A, Winkler D, Kienle D, Busch R, Emmerich B et al. VH mutation status and genomic aberrations in Binet-A CLL. Relation to risk-stratification and progression free survival in the CLL1 trial of the German CLL Study Group. Onkologie 2003;26(Suppl. 5):8 (Abstract 181).
23. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7.
24. Keating MJ. Management of chronic lymphocytic leukemia: a changing field. Rev Clin Exp Hematol 2002;6:350-65.
25. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002;16:985-92.
26. Lindsay MA. Target discovery. Nature Rev Drug Discovery 2003;2:831-8.
27. Clarke PA, te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development, progress and potential. Biochem Pharmacol 2001;62:1311-36.
28. Butte A. The use and analysis of microarray data. Nature Rev Drug Discov 2001;1:951-60.
29. Zhang MQ. Extracting functional information from microarrays: a challenge for functional genomics. Proc Natl Acad Sci USA 2002;99:12509-11.
30. Slonim DK. From patterns to pathways: gene expression data analysis comes of age. Nature Genet 2002;32:502-8.
31. Knowles J, Gromo G. A guide to drug discovery: Target selection in drug discovery. Nature Rev Drug Discov 2003;2:63-9.
32. Hopkins AL, Groom CR. The druggable genome. Nature Rev Drug Discov 2002;1:727-30.
33. Gaiger A, Carter L, Mannion-Henderson J, Ordonez N, Kusec R, Jaksic B et al. Identification of genes associated with B-cell and T-cell neoplasms using a combination of cDNA PCR subtraction and microarray analysis. Blood 2001;98(Suppl. 1):Abstract 1389.
34. Diamond DL, Zhang Y, Gaiger A, Smithgall M, Vedvick TS, Carter D. Use of ProteinChip array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify thymosin β-4, a differentially secreted protein from lymphoblastoid cell lines. J Am Soc Mass Spectrom 2003;14:760-5.
35. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
36. Staudt LM. Gene expression profiling of lymphoid malignancies. Annu Rev Med 2002;53:303-18.
37. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003;1:346-61.
38. Keating MJ, O'Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 2002;29:70-4.
39. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507-13.
40. Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P et al. CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 2001;91:474-80.
41. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-14.
42. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
43. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
44. Rai KR, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 2003;348:1797-9.
45. Heintel D, Kroemer E, Schwarzinger I, Stilgenbauer S, Streubel B et al. Association of ZAP-70 mRNA expression levels with other prognostc factors in chronic lymphocytic leukemia. Hematol J 2003;4(Suppl. 2):138 (Abstract 447).
46. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74.
47. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP et al. kappa B2/p100 induces Bcl-2 expression. Leukemia 2003;17:1349-56.
48. Cheson BD. Hematologic malignancies: new developments and future treatments. Semin Oncol 2002;29(Suppl. 13):33-45.
49. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999;274:18470-6.
50. Jacobs H, Brass L. Towards an understanding of somatic hypermutation. Curr Opin Immunol 2001;13:208-18.
51. Martin A, Scharff MD. Somatic hypermutation of the AID transgene in B and non-B cells. Proc Natl Acad Sci USA 2002;99:12304-8.
52. Cerutti A, Zan H, Kim EC, Shah S, Schattner EJ et al. Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells. J Immunol 2002;169:6594-603.
53. Greeve J, Philipsen A, Krause K, Klapper W, Heidorn K et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin's lymphomas. Blood 2003;101:3574-80.
54. Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C et al. Chronic lymphocytic leukemia B cells expressing AID display a dissociation between class switch recombination and somatic hypermutation. Blood 2003;101:4029-32.
55. McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor prognosis chronic lymphocytic leukemia. Blood 2003;101:4903-8.
56. Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiß A et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 2004;18:756-62.
57. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 2002;99:3742-7.
58. Rabbani H, Mikaelsson E, Daneshmanesh AH, Luppert A, Tehrani MJ, Rezvany MR et al. Fibromodulin, a novel tumor-associated antigen exclusively expressed in tumor B-cells from all patients with chronic lymphocytic leukaemia. Hematol J 2003;4(Suppl. 2):133 (Abstract 433).
59. Jäger U. Innovative strategies in lymphoma therapy. Wien Klin Wochenschr 2003;115:462-70.
60. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96:2917-24.
61. Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology (Am Soc Hematol Educ Program) 2002;1:241-62.
62. Soede RD, Wijnands YM, Van Kouteren-Cobzaru I, Roos E. ZAP-70 tyrosine kinase is required for LFA-1-dependent T cell migration. J Cell Biol 1998;142:1371-9.
63. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL. association with protein kinase Cδ. Blood 2002;100:3741-8.
64. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-85.
65. Sandor V, Senderowicz A, Sackett D. Depsipeptide causes G1 cell cycle arrest through disruption of signal transduction through MAP kinase. Proc Am Assoc Cancer Res 1998;39:A3812.
66. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999;94:1401-8.
67. Virchis A, Ganeshaguru K, Hart S, Jones D, Fletcher L, Wright F et al. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J 2002;3:131-6.
68. O'Brien S, Giles F, Rai K, Andreef M, Cunningham C, Frankel S et al. Bcl-2 antisense (Genasense) as monotherapy for refractory chronic lymphocytic leukemia. Blood 2001;98(Suppl. 1):772a (Abstract 3213).
69. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-33.
70. Zeis M, Siegel S, Schmitz N, Dreger P. Survivin is a suitable target molecule for T-cell based immunotherapy in patients with B-CLL. Leukemia Lymph Year?;44(Suppl. 2):31 (Abstract 65).